With permission from Semmelweis at American Greatness

How Government Is Standing in the Way of Lifesaving American Innovation

President Trump could order his administration to use America’s companies and tell his public health authorities that they’ve done quite enough—which is to say they’ve done far too little to prepare for the crisis.

We should use American companies to do contact tracing of the ill, and allow start-ups that want to administer at-home coronavirus tests to do so. Yet rather than acknowledge that extraordinary circumstances require extraordinary dispensations, our FDA stops U.S. innovators at every turn, preferring to do business with intellectual property thieves like the Chinese Communist-backed Beijing Genomics Institute, a state-owned entity currently in yet another legal fight with an American company.

TRENDING: ANGRY LEFTIST Smacks 84-Year-Old Female Trump Supporter Across the Face at Trump Rally in Aliso Viejo -- Beats Another Senior (VIDEO)

President Trump Needs To Tell Fauci, the NIH, and the FDA: “You’re Fired!”

Recent history provides too many examples of institutional failure. We have already examined how lacking Dr. Anthony Fauci is now and has been before and during the HIV/AIDS crisis. He is a fraud. Whether he is a crook or a fool is perhaps open to interpretation.

“Despite President Donald Trump’s enthusiasm for the drug hydroxychloroquine to treat coronavirus, the federal funding powerhouse led by Dr. Anthony Fauci isn’t spending any money on it, and clinical trials for it are lagging behind other drug studies,” CNN reports.

Instead Fauci has been touting Remdesivir from Gilead through the National Institute of Allergy and Infectious Diseases (NIAID). Gilead’s Remdesivir costs thousands of dollars and works less well than hydroxychloroquine—a generic that has worked all over the world. Remdesivir requires intravenous administration and has stronger side effects.

Why is the good doctor pushing a bad cure?

What motivates Fauci, as anyone can see from his many interviews and long career, is fame.

Vanity must be his favorite of the seven deadly sins. And deadly it has been—just not for Fauci. HIV/AIDS activists wisely picked up on this character trait and shamed Fauci into doing more after years of inaction, as even fawning portrayals of Fauci acknowledge. ACT UP, having bent Fauci to its will, finally got him to act—but not before thousands of gay men perished. Then, as now, Fauci left patients in limbo while he cultivated his ties to the drug manufacturers.

Fauci works closely with Gilead and other drug manufacturers. Once again Gilead has helped advance Fauci’s public persona while he has advanced their drugs, sometimes even against the interests of the U.S. government or HIV/AIDS patients.

Fauci even praised a Gilead television ad for Truvada, or PreP, a $1,000-a-month drug. It’s illegal in most countries for pharmaceutical companies to advertise, but Fauci found much to like in the ad. He had reason to. After all, his organization funded the study with your money.

“What I really liked about the ad is it didn’t just say go get on PrEP; it said get tested,” Fauci told NBC News in 2018. “A, get tested. B, there are more options to protect yourself.”

Fauci has also spoken at events funded by Gilead and other pharmaceutical companies.

Later, President Trump’s HHS sued Gilead alleging that the drug manufacturer had profited from millions of taxpayer funded research dollars against the interests of patients. Gilead lost the suit right around the time it needed a new drug to help it take off. With few drugs available for the coronavirus, Daniel O’Day, Gilead’s new CEO only been on the job months—turned to Remdesivir, a drug marketed toward solving the Ebola virus. Remdesivir failed at that, too. Indeed Congolese officials found too expensive and too ineffective compared to cheaper alternatives.

“The results were most striking for patients who received treatments soon after becoming sick, when their viral loads were still low—death rates dropped to 11 percent with mAb114 and just 6 percent with Regeneron’s drug, compared with 24 percent with ZMapp and 33 percent with Remdesivir,” wrote Wired’s Megan Molteni.

Sound familiar? The same thing has been true of the ultracheap hydroxychloroquine which has proven effective nearly everywhere it’s been tried—if tried early enough.

Early indications from a larger controlled trial for chloroquine– Still over multiple facilities, groups likely determined by facility again, but this one examines both viral RNA testing and symptoms. Results are favorable. Hope to see survival figures when paper comes out. https://t.co/qEaRrKLNK7 — ice9 (@__ice9) March 28, 2020

For this reason alone, it is unconscionable that there are delays in testing results, thanks to the FDA’s byzantine rules that make it easier for Communist Chinese companies to test while hobbling U.S. firms.

Gilead is left with a huge stockpile of Remdesivir that is too expensive and too unnecessary—they’ll have more on the way once they are approved, they promise! Fauci has once again used taxpayer resources to force patients into a lengthy and ridiculous clinical trial process for the drug—only this time its Americans desperate for hope as opposed to Africans. If at first you don’t succeed, fail, fail, fail again.

With Fauci’s credibility invested in Gilead, we ought to ask to see Fauci and his family’s portfolio too, especially after he publicly admitted that he would take hydroxychloroquine.

Then again, it’s amazing how cheaply some people, especially scientists, will sell out.

Indeed, putting politics and press conferences ahead of pharmacology has been the medical establishment’s raison d’être as it offloads the costs of its expensive labs and bureaucracy. Dr. Francis Collins’s NIH, for example, charges the government thousands of dollars for genetic sequencing that costs the private sector just hundreds.

Read the rest here.